Scancell Holdings (GB:SCLP) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Scancell Holdings has announced that Genmab has exercised its option for a second commercial license agreement, granting Genmab exclusive rights to develop and commercialize a monoclonal antibody from Scancell’s GlyMab® platform. This move could potentially yield Scancell up to $630 million in milestone payments and royalties from net sales. This strategic partnership highlights Scancell’s innovative approach in developing therapeutics targeting cancer-specific glycans.
For further insights into GB:SCLP stock, check out TipRanks’ Stock Analysis page.